S&P 500 7,609.78 +0.13% NASDAQ 27,093.90 +0.03% DOW 51,307.79 +0.45% R2K 2,931.96 +0.90%
Next Bullish Trade
TMO Thermo Fisher Scientific Inc. NYQ
$482.08 -11.96 (-2.42%)
Neutral · +0.89σ Grade C
+ Compare Set alert Open in Sniper

Price chart

Overlay: Click earnings ▲ markers for day-move details

Loading 1Y daily…

Financial overlay · last 12 quarters

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $11.0B $1.7B $1.9B $0.8B 15.0% 17.4%
2025-12-31 $12.2B $2.0B $2.3B $3.0B 16.1% 18.9%
2025-09-30 $11.1B $1.6B $2.1B $1.8B 14.5% 18.7%
2025-06-30 $10.9B $1.6B $1.9B $1.1B 14.9% 17.7%
2025-03-31 $10.4B $1.5B $1.8B $0.4B 14.5% 17.5%

Earnings replay · last 20 reports

DateEPS actual EPS estSurprise
2026-04-23 5.44 5.24 +3.8%
2026-01-29 5.21 5.20 +0.2%
2025-10-22 5.79 5.50 +5.3%
2025-07-23 5.36 5.23 +2.5%
2025-04-23 5.15 5.10 +0.9%
2025-01-30 6.10 5.94 +2.7%
2024-10-23 5.28 5.25 +0.5%
2024-07-24 5.37 5.13 +4.7%
2024-04-24 5.11 4.71 +8.4%
2024-01-31 5.67 5.65 +0.4%
2023-10-25 5.69 5.61 +1.4%
2023-07-26 5.15 5.43 -5.2%
2023-04-26 5.03 5.03 -0.1%
2023-02-01 5.40 5.20 +3.8%
2022-10-26 5.08 4.82 +5.5%
2022-07-28 5.51 4.98 +10.6%
2022-04-28 7.25 6.21 +16.8%
2022-02-02 6.54 5.27 +24.0%
2021-10-27 5.76 4.70 +22.7%
2021-07-28 5.60 5.47 +2.3%

Earnings markers are overlaid on the price chart above. Transcript summaries require PERPLEXITY_API_KEY (deferred to a follow-up).

Peer comparison · Healthcare

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
LLY $949B 37.7 23.9 13.1 27.3 30.5 82.8% 55.5% 169.9% 0.96%
UNH $343B 28.5 18.1 0.8 18.5 3.5 18.8% 2.0% 0.7% 5.15%
JNJ $537B 25.8 17.5 5.6 16.6 6.6 68.0% 9.9% -52.9% 2.33%
MRK $286B 32.6 12.1 4.3 11.2 6.2 76.7% 4.9% — 4.92%
ABBV $381B 105.1 13.3 6.1 14.8 -57.2 72.0% 12.4% -46.2% 5.47%
PFE $146B 19.5 9.0 2.3 7.8 1.6 74.8% 5.4% -10.1% 8.50%
TMO ★ $179B 26.5 17.7 4.0 19.4 3.4 40.9% 6.2% 11.3% 3.08%
ABT $151B 24.4 14.3 3.4 15.2 2.9 56.5% 7.8% -19.7% 4.19%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Top institutional holders

Top-10 concentration: 34.45%

HolderShares% out
Blackrock Inc. 30,427,192 8.19%
Vanguard Capital Management LLC 24,280,816 6.53%
State Street Corporation 16,731,668 4.50%
Morgan Stanley 10,863,528 2.92%
FMR, LLC 10,776,436 2.90%
Geode Capital Management, LLC 8,407,891 2.26%
Franklin Resources, Inc. 6,813,031 1.83%
JPMORGAN CHASE & CO 6,795,482 1.83%
Capital World Investors 6,646,316 1.79%
Price (T.Rowe) Associates Inc 6,315,471 1.70%

Insider activity · 90d

No insider trades for TMO in last 90d.

Analyst estimates

yfinance
Low
$490.0
Mean
$611.56
High
$750.0
Analysts
25

Consensus: strong_buy (mean 1.40741). Distribution requires FINNHUB_API_KEY.

SEC filings

FormFiled DescriptionAction
8-K 2026-05-26 8-K view ·
4 2026-05-22 PRIMARY DOCUMENT view ·
4 2026-05-22 PRIMARY DOCUMENT view ·
4 2026-05-22 PRIMARY DOCUMENT view ·
4 2026-05-22 PRIMARY DOCUMENT view ·
4 2026-05-22 PRIMARY DOCUMENT view ·
4 2026-05-22 PRIMARY DOCUMENT view ·
4 2026-05-22 PRIMARY DOCUMENT view ·
4 2026-05-22 PRIMARY DOCUMENT view ·
4 2026-05-22 PRIMARY DOCUMENT view ·
4 2026-05-22 PRIMARY DOCUMENT view ·
10-Q 2026-05-01 10-Q view ·
4 2026-04-29 PRIMARY DOCUMENT view ·
8-K 2026-04-23 8-K view ·
DEF 14A 2026-04-07 DEF 14A view ·
4 2026-03-31 PRIMARY DOCUMENT view ·
4 2026-03-31 PRIMARY DOCUMENT view ·
4 2026-03-31 PRIMARY DOCUMENT view ·
4 2026-03-31 PRIMARY DOCUMENT view ·
4 2026-03-31 PRIMARY DOCUMENT view ·
8-K 2026-03-24 8-K view ·
4 2026-03-12 PRIMARY DOCUMENT view ·
4 2026-03-09 PRIMARY DOCUMENT view ·
4 2026-03-05 PRIMARY DOCUMENT view ·
4 2026-03-02 PRIMARY DOCUMENT view ·
4 2026-03-02 PRIMARY DOCUMENT view ·
4 2026-03-02 PRIMARY DOCUMENT view ·
4 2026-03-02 PRIMARY DOCUMENT view ·
4 2026-03-02 PRIMARY DOCUMENT view ·
4 2026-03-02 PRIMARY DOCUMENT view ·
4 2026-03-02 PRIMARY DOCUMENT view ·
4 2026-03-02 PRIMARY DOCUMENT view ·
4 2026-02-27 PRIMARY DOCUMENT view ·
4 2026-02-27 PRIMARY DOCUMENT view ·
4 2026-02-27 PRIMARY DOCUMENT view ·
4 2026-02-27 PRIMARY DOCUMENT view ·
4 2026-02-27 PRIMARY DOCUMENT view ·
4 2026-02-27 PRIMARY DOCUMENT view ·
4 2026-02-27 PRIMARY DOCUMENT view ·
4 2026-02-27 PRIMARY DOCUMENT view ·
4 2026-02-27 PRIMARY DOCUMENT view ·
10-K 2026-02-26 10-K view ·
8-K 2026-02-12 8-K view ·
4 2026-02-11 PRIMARY DOCUMENT view ·
8-K 2026-01-29 8-K view ·
8-K 2026-01-12 8-K view ·
4 2026-01-05 PRIMARY DOCUMENT view ·
4 2026-01-05 PRIMARY DOCUMENT view ·
4 2026-01-05 PRIMARY DOCUMENT view ·
4 2026-01-05 PRIMARY DOCUMENT view ·
4 2026-01-05 PRIMARY DOCUMENT view ·
4 2025-12-11 PRIMARY DOCUMENT view ·
4 2025-12-05 PRIMARY DOCUMENT view ·
4 2025-12-04 PRIMARY DOCUMENT view ·
4 2025-12-03 PRIMARY DOCUMENT view ·
4 2025-12-03 PRIMARY DOCUMENT view ·
8-K 2025-12-01 8-K view ·
4 2025-11-26 PRIMARY DOCUMENT view ·
4 2025-11-17 PRIMARY DOCUMENT view ·
4 2025-11-14 PRIMARY DOCUMENT view ·

About

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of a…